---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-22-033756"
form_type: "8-K"
ticker: "TARA"
cik: "0001359931"
company_name: "Protara Therapeutics, Inc."
filed_at: "2022-06-21T23:59:59+00:00"
generated_at: "2026-06-25T00:18:06.971876+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Protara Therapeutics CFO Blaine Davis to depart July 15, 2022

## Summary
- CFO Blaine Davis leaving to pursue other opportunities, effective July 15, 2022; resignation not due to disagreements.
- Separation agreement: 12-month base salary lump sum, target bonus, COBRA and life insurance premiums, accelerated equity vesting.
- Company had $119M cash, cash equivalents and investments as of March 31, 2022, expected to fund operations into mid-2024.
- CEO Jesse Shefferman thanked Davis for building finance, commercial, and IT functions.

## SEC filing metadata
- accession: 0001213900-22-033756
- form_type: 8-K
- ticker: TARA
- cik: 0001359931
- company_name: Protara Therapeutics, Inc.
- filed_at: 2022-06-21T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1359931/000121390022033756/0001213900-22-033756-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1359931/000121390022033756/ea161829-8k_protara.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-22-033756
- JSON: https://secwatch.observer/filing/0001213900-22-033756.json
- Plain text: https://secwatch.observer/filing/0001213900-22-033756.txt

## Key facts
- Executive change
  Blaine Davis departed as Chief Financial Officer at Protara Therapeutics, Inc..
  - Action: leaving
  - Role: Chief Financial Officer
  source text: On June 21, 2022 Protara Therapeutics, Inc. (the “Company”) announced that Blaine Davis, Chief Financial Officer of the Company, will be leaving the Company to pursue other opportunities effective as of July 15, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1359931/000121390022033756/0001213900-22-033756-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.